Gelatin is a versatile substance that is used in many different industries for its unique properties. In the pharmaceutical industry, gelatin has an important role for a variety of reasons. Gelatin is extracted collagen, which is found in the skin, bones, and connective tissues of animals. The demand for this ingredient is increasing in the pharma industry due to its versatility and unique properties. In this blog, we will explore the properties of pharmaceutical gelatin and its various applications in the expanding pharmaceutical gelatin market.
Some of Its Properties Include:
- Gelling ability
- Compatibility
- Minimal immunogenicity
- High purity
- Transparency
- Low endotoxin levels
- Stability
- Solubility
- Safety
- cost-effective
The global pharmaceutical gelatin market was valued at USD 1.24 billion in 2022 and is expected to reach USD 2.17 billion at a CAGR of 5.8% during the forecast period.
What Factors Are Driving the Market Growth?
- Pharmaceutical gelatin’s diverse applications: The rising use of gelatin in biomedical, gene therapy, tissue engineering, intrinsic and cosmetic applications, wound healing, and wound dressing is driving the market growth. The expected expansion of the market is attributed to the increasing demand for gelatin in functional food sectors, owing to its ability to potentially prevent a range of diseases, improve food quality, and provide food protection.
- Gelatin nanoparticles for parenteral formulations: Due to their affordability, biocompatibility, low antigenicity, and versatility in different formulations, gelatin nanoparticles have been proposed as a suitable option for parenteral formulations. This is anticipated to boost demand for parenteral drug delivery systems, leading to an increase in market growth.
- Gelatin in sustained-release formulations for chronic illnesses: Globally, chronic conditions like diabetes, cancer, and cardiovascular illnesses are on the rise. Since these illnesses require long-term treatment, pharmaceutical gelatin will likely become more and more popular as a key component in sustained-release formulations.
Recent Research in The Industry
- In March 2021, a study published in PubMed unveiled that pharmaceutical gelatin has a multitude of uses, such as capsule manufacturing, micro- or oil-coating, tablet coating, emulsion stabilization, and delivery methods that employ microspheres, nanospheres, scaffolds, microneedles, and hydrogels.
- In November 2021, a study published on Springer Link revealed that gelatin has the potential to deliver drugs for tumor therapy, including doxorubicin, cycloheximide, and resveratrol, due to its biodegradable and biocompatible properties.
- In May 2022, a study titled Gelatin Stabilises Nebulized Proteins in Pulmonary Drug Delivery Against COVID-19 revealed that adding gelatin to drug delivery greatly boosts the stability and activity of proteins following nebulization, allowing for lower dosages of medication. Gelatin will probably be used more frequently in pharmaceutical products as a result of its benefits in treating COVID-19 patients.
Regional Market Demand
North America is expected to witness the largest pharmaceutical gelatin market share in 2022. A strong pharmaceutical industry, expanding R&D efforts, and increasing demand for pharmaceutical products are all factors in the region’s market expansion. The United States is the main market for pharmaceutical gelatin in North America, owing to the presence of key gelatin manufacturers, growing demand for nutraceuticals, and increasing investment in R&D activities.
Some of The Top Players in The Market
Tessenderlo Group, Rousselot, Nitta Gelatin Inc., Gelita AG, Catelent Inc., Capsugel, Norland Products Inc, Roxlor llc, Weishardt, and Trobas Pharmaceutical Gelatine B.V, Sterling Gelatin, Aspire Pharmaceuticals, Junca Gelatines, Gelco International, Lapi Gelatine S.p.a.
Recent Developments
- In 2022, Lonza enhanced their Capsugel contribution with a white hard gelatin capsule that was titanium dioxide-free (TiO2-free) in response to the necessity for the food industry to fulfill the criteria for foods in the European Union.
- In May 2021, The X-Pure GelDAT Darling Ingredients Inc.’s Rousselot brand of refined pharmaceutical-grade modified gelatin launched gelatin desaminotyrosine for biomedical uses.